These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9626462)
1. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Lehnert M; Mross K; Schueller J; Thuerlimann B; Kroeger N; Kupper H Br J Cancer; 1998 Apr; 77(7):1155-63. PubMed ID: 9569055 [TBL] [Abstract][Full Text] [Related]
3. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Rivera E; Valero V; Esteva FJ; Syrewicz L; Cristofanilli M; Rahman Z; Booser DJ; Hortobagyi GN Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909 [TBL] [Abstract][Full Text] [Related]
4. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034 [TBL] [Abstract][Full Text] [Related]
5. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622 [TBL] [Abstract][Full Text] [Related]
6. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653 [TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444 [TBL] [Abstract][Full Text] [Related]
9. Current options in treatment of anthracycline-resistant breast cancer. Kröger N; Achterrath W; Hegewisch-Becker S; Mross K; Zander AR Cancer Treat Rev; 1999 Oct; 25(5):279-91. PubMed ID: 10544072 [TBL] [Abstract][Full Text] [Related]
11. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. Wilson WH; Bates SE; Fojo A; Bryant G; Zhan Z; Regis J; Wittes RE; Jaffe ES; Steinberg SM; Herdt J J Clin Oncol; 1995 Aug; 13(8):1995-2004. PubMed ID: 7636540 [TBL] [Abstract][Full Text] [Related]
12. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710 [TBL] [Abstract][Full Text] [Related]
13. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. O'connor T; Rustum Y; Levine E; Creaven P Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973 [TBL] [Abstract][Full Text] [Related]
14. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033 [TBL] [Abstract][Full Text] [Related]
15. Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer. Kellokumpu-Lehtinen P; Lantto A; Kokko R; Elomaa L; Järvenpää R; Lehtinen R; Blomqvist C Int J Clin Pharmacol Res; 2002; 22(2):47-53. PubMed ID: 12503775 [TBL] [Abstract][Full Text] [Related]
16. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy resistance in breast cancer. Lehnert M Anticancer Res; 1998; 18(3C):2225-6. PubMed ID: 9703789 [TBL] [Abstract][Full Text] [Related]
18. Clinical reversal of multidrug resistance. Bates SE; Wilson WH; Fojo AT; Alvarez M; Zhan Z; Regis J; Robey R; Hose C; Monks A; Kang YK; Chabner B Stem Cells; 1996 Jan; 14(1):56-63. PubMed ID: 8820952 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects. Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142 [TBL] [Abstract][Full Text] [Related]
20. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study. Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]